More capital isn't always better. An excess of funding can lead to a lack of focus, wasteful spending, and a reluctance to make tough choices—a form of moral hazard. It's crucial to match the amount of capital to a founder's ability to deploy it effectively without losing discipline.

A huge Series A before clear product-market fit creates immense pressure to scale prematurely. This can force 'unnatural acts' and unrealistic expectations, potentially leading the company to implode. It challenges the 'more money is always better' mindset at the early stages.

Many startups scale revenue based on VC expectations or by mimicking fast-growing companies like Snowflake, rather than using internal business signals. This inappropriate timing and pacing, often triggered by a capital infusion, leads to a high, unnecessary failure rate.

Flexport's CEO advises founders who've raised a large round to immediately implement a 90-day hiring freeze. This prevents the team from defaulting to hiring as the solution to every problem, reinforcing a culture of internal problem-solving and preventing the new capital from creating bloat and slowing the company.

Raising too much money at a high valuation puts a "bogey on your back." It forces a "shoot the moon" strategy, which can decrease capital efficiency, make future fundraising harder, and limit potential exit opportunities by making the company too expensive for acquirers.

Beyond product-market fit, there is "Founder-Capital Fit." Some founders thrive with infinite capital, while for others it creates a moral hazard, leading to a loss of focus and an inability to make hard choices. An investor's job is to discern which type of founder they're backing before deploying capital that could inadvertently ruin the company.

While capital is necessary, an overabundance is dangerous. Large secondaries can make founders comfortable and misaligned with investors. Excessive primary capital leads to bloat, unfocused strategy, and removes the pressure that drives invention. This moral hazard often leads to worse outcomes than being capital-constrained.

A common failure mode for well-funded biotechs is growing headcount too rapidly. Immunocore's CEO advises new leaders to pace themselves, emphasizing that drug development is a marathon. Prematurely scaling creates fixed expenses that can drain capital before key scientific milestones are hit.

Chasing high, unrealized valuations is dangerous. It makes common stock prohibitively expensive, undermining the potential for life-changing wealth for employees—a key recruiting tool. It also narrows a company's strategic options, locking it into a high-stakes path where anything less than exceeding the last valuation is seen as failure.